Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors
Endocrine - Related Cancer , Volume 21 - Issue 4 p. 601- 613
The mTOR pathway has recently been suggested as a new potential target for therapy in adrenocortical carcinomas (ACCs). The aim of the current study is to describe the expression of the mTOR pathway in normal adrenals (NAs) and pathological adrenals and to explore whether there are correlation between the expression of these proteins and the in vitro response to sirolimus. For this purpose, the MTOR, S6K1 (RPS6KB1), and 4EBP1 (EIF4EBP1) mRNA expression were evaluated in ten NAs, ten adrenal hyperplasias (AHs), 17 adrenocortical adenomas (ACAs), and 17 ACCs by qPCR, whereas total(t)/phospho(p)-MTOR, t/p-S6K, and t/p-4EBP1 protein expression were assessed in three NAs, three AHs, six ACAs, and 20 ACCs by immunohistochemistry. The effects of sirolimus on cell survival and/or cortisol secretion in 12 human primary cultures of adrenocortical tumors (ATs) were also evaluated. In NAs and AHs, layer-specific expression of evaluated proteins was observed. S6K1 mRNA levels were lower in ACCs compared with NAs, AHs, and ACAs (P<0.01). A subset of ATs presented a moderate to high staining of the evaluated proteins. Median t-S6K1 protein expression in ACCs was lower than that in ACAs (P<0.01). Moderate to high staining of p-S6K1 and/or p-4EBP1 was observed in most ATs. A subset of ACCs not having moderate to high staining had a higher Weiss score than others (P<0.029). In primary AT cultures, sirolimus significantly reduced cell survival or cortisol secretion only in sporadic cases. In conclusion, these data suggest the presence of an activated mTOR pathway in a subset of ATs and a possible response to sirolimus only in certain ACC cases.
|Adenoma, Adrenal cortex, Adrenocortical cancer, Carcinoma, Immunohistochemistry, mTOR, Primary cultures|
|Endocrine - Related Cancer|
|Organisation||Department of Internal Medicine|
de Martino, M.C, Feelders, R.A, de Herder, W.W, van Koetsveld, P.M, Dogan, F, Janssen, J.A.M.J.L, … Hofland, L.J. (2014). Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. Endocrine - Related Cancer, 21(4), 601–613. doi:10.1530/ERC-13-0112